Institutional Grade Dual-Therapy
Rozclue F10
Advanced Dual-Action Lipid Management
Synergy of Rosuvastatin & Fenofibrate for Comprehensive
Dyslipidemia Control. Engineered for clinical precision in
managing complex lipid profiles.
Therapeutic Indications
Rozclue F10 is indicated for the treatment of adult patients with highly complex
lipid profiles requiring institutional management.
Mixed Dyslipidemia
Effective for patients with elevated
LDL-C and TG, combined with low
levels of HDL-C.
Hypercholesterolemia
Primary hypercholesterolemia
management where monotherapy is
insufficient for target levels.
Risk Reduction
Significant reduction in cardiovascular
risk, including heart attack and stroke
prevention.
Dual-Path Lipid Control
ABS Pharmaceutical offers enterprise-grade distribution solutions
for hospitals, pharmacy chains, and clinical healthcare providers.
Rosuvastatin Action
Selective and competitive inhibition of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3- methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol.
Fenofibrate Activation
Activation of Peroxisome Proliferator Activated Receptor-alpha (PPAR-α). Through activation of PPAR-α, fenofibrate increases the lipolysis and elimination of triglyceride-rich particles from plasma.
Clinical Cautions
ABSORPTION WARNING
Avoid antacids 2 hours before/after
to ensure optimal absorption.
MEDICAL DISCLOSURE
Tell your doctor if you are pregnant,
breastfeeding, or on other
medications.
SIDE
EFFECTS
Report severe diarrhea, vomiting, or
constipation to your clinician.